Navigation Links
Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
Date:6/1/2009

Abstract # 6053

ORLANDO, Fla., June 1 /PRNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data demonstrating the feasibility of long-term, low-dose adjuvant chemotherapy, which resulted in fewer tumor recurrences and cancer metastases in patients with locally advanced head and neck squamous cell carcinoma. The findings were announced today at the 2009 American Society of Clinical Oncology Annual Meeting.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO )

Karmanos researchers discovered that when they utilized oral chemotherapy agent capecitabine, also known by its pharmaceutical name Xeloda, on 35 study patients over approximately 36 months, the survival rate for 97 percent of those patients was two years and the three-year progression free survival rate was 86 percent.

Research was supervised by George Yoo, M.D., chief medical officer and member of the Head and Neck Cancer Multidisciplinary Team at Karmanos. Ammar Sukari, M.D., assistant professor of medicine and fellow member of the Head and Neck Cancer Multidisciplinary Team, conducted the poster presentation.

"What the study found is that low-dose, long-term adjuvant therapy is feasible," said Dr. Yoo. "We are pleased with the results. There was a relatively low recurrence rate for the tumors."

Approximately 40,000 new cases of head and neck squamous cell carcinoma (HNSCC) cases are diagnosed each year, according to Dr. Yoo. A higher proportion of men are diagnosed with carcinomas - approximately four to one as compared to women. Chemotherapy for HNSCC is typically rigorous and even then, 40 to 60 percent of patients experience recurring carcinoma tumors. The survival rate for advanced HNSCC is less than 40 percent.

The exploration of low-dose, long-term oral chemotherapy agents in adjuvant (i.e. follow-up) cancer treatment represents new and exciting territory for Karmanos scientists. Capecitabine was the first FDA-approved oral chemotherapy treatment, gaining approval for human use in 1998. Since then, other oral cancer agents have been developed, including Tamoxifen for breast cancer patients and Methotrexate, which is used to treat breast, skin, head, neck and lung cancers.

"There are not many low-dose applications for oral chemotherapy," Dr. Yoo said. "Intravenous chemotherapy is still the norm. From the innovation stand-point, it's really a new way of looking at chemotherapy."

Karmanos' study is investigator-initiated in which researchers worked with capecitabine's manufacturer Roche to perform the study. Dr. Yoo said Karmanos continues to enroll patients in the Phase II study and hopes that down the road, the study will enter a third phase.

"We thought it was a good study, one that explores the effects of low-dose, long-term oral chemotherapy treatments," said Dr. Yoo. He added that not only does low-dose, long-term adjuvant therapy for HNSCC patients promise longer survival and lower recurrence of tumors, it's an easy treatment method, one with minimum side effects, and one that would ensure all patients could undergo adjuvant therapy.

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
2. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
3. Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD)
4. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
5. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
6. Researchers Discover Metabolite Linked to Aggressive Prostate Cancer
7. Why Wait for an Anti-Aging Drug? Researchers Interviewed on CBS-TVs 60 MINUTES Discover Longevinex(R) Nutriceutical Matrix Activates 9-Fold More Longevity Genes than Plain Resveratrol
8. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
9. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
10. Researchers at Axial Biotech Develop a DNA Test for Scoliosis
11. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):